A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis
Ventyx – VTX2735-202
What is the goal of the study?
The role of NLRP3 (NACHT, LRR and pyrin domains-containing protein 3) has been established in the pathogenesis of inflammatory conditions including pericarditis. Prior nonclinical research confirmed the expression and activation of the NLRP3 inflammasome in human pericardial specimens and in a mouse pericarditis model; however, the therapeutic potential of NLRP3 inflammasome inhibition is unknown in the treatment of inflammatory diseases like recurrent pericarditis (RP). In this study, individuals with RP will receive open-label VTX2735, a novel compound that selectively inhibits the NLRP3 inflammasome. This Phase 2a study is being conducted to evaluate the safety/tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of VTX2735 in participants with RP.
Who can participate in the study?
Everyone